TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $40.67.

Several research analysts have recently commented on the company. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th.

Institutional Trading of TG Therapeutics

Several hedge funds have recently modified their holdings of the company. Barclays PLC increased its holdings in shares of TG Therapeutics by 83.9% in the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock worth $8,117,000 after buying an additional 158,323 shares during the last quarter. Synovus Financial Corp bought a new stake in TG Therapeutics during the third quarter worth approximately $465,000. Franklin Resources Inc. lifted its stake in shares of TG Therapeutics by 3.8% in the 3rd quarter. Franklin Resources Inc. now owns 128,985 shares of the biopharmaceutical company's stock valued at $2,945,000 after purchasing an additional 4,756 shares during the last quarter. Principal Financial Group Inc. lifted its position in TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock worth $18,061,000 after buying an additional 725,371 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in TG Therapeutics by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock valued at $16,859,000 after purchasing an additional 270,286 shares during the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Stock Performance

TGTX traded up $1.03 during trading on Thursday, hitting $41.33. 1,464,365 shares of the company traded hands, compared to its average volume of 3,086,120. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The firm has a market cap of $6.56 billion, a P/E ratio of -413.26 and a beta of 2.14. The stock's fifty day moving average is $37.18 and its 200 day moving average is $32.52. TG Therapeutics has a one year low of $12.93 and a one year high of $43.32.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. As a group, equities analysts predict that TG Therapeutics will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.